Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
-
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
-
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
-
Open Letter to Shareholders
-
TransCode Therapeutics Announces Nasdaq Extension to Re-gain Compliance
-
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review o
-
TransCode Therapeutics Completes Initial Dosing of First Co-hort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
-
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
-
PrismHR Unveils New Unified Employee Experience (UEX)
-
Kevin Andrews Named President of PrismHR